Pfizer asks FDA to expand COVID-19 vaccine authorization to include 12- to 15-year-olds
Shares of Pfizer Inc. gained 1% in trading on Friday after the drug maker said it requested that the emergency-use authorization
Portions of Pfizer Inc. acquired 1% in exchanging on Friday after the medication creator said it mentioned that the crisis use approval for its COVID-19 antibody be revised to incorporate adolescents between the ages of 12 and 15. The antibody is presently approved for individuals who are at any rate 16 years of age in the U.S. Pfizer said a Phase 3 clinical preliminary in 12-to 15-year-olds tracked down that the antibody is 100% viable and had a comparative result profile to past examination members between the ages of 16 and 25. Pfizer built up the antibody with BioNTech SE . Pfizer's stock is down 1.3% since the beginning of the year, while the more extensive S&P 500 is up 8.5%.